| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/09/2001 | WO2001056590A2 Utilization of protein kinase inhibitor alpha |
| 08/09/2001 | WO2001056585A1 Cognitive enhancer comprising ginseng extract |
| 08/09/2001 | WO2001056579A1 Methods for treating alzheimer's disease |
| 08/09/2001 | WO2001056577A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
| 08/09/2001 | WO2001056576A1 Transdermal therapeutic system for the administration of zaleplon |
| 08/09/2001 | WO2001056567A1 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| 08/09/2001 | WO2001056562A1 Stable emulsion compositions |
| 08/09/2001 | WO2001056559A1 Aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent |
| 08/09/2001 | WO2001056532A2 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 08/09/2001 | WO2001056358A2 Enhanced propertied pesticides |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001019337A3 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001014376A8 Novel spiro compounds |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001005940A3 Methods for producing and preparing cells for cell therapy |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2000075144A8 Peroxynitrite decomposition catalysts and methods of use thereof |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000069257A3 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 08/09/2001 | WO2000057862A3 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 08/09/2001 | WO2000055072A3 Aerosol metering valve |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012855 Administering to the mammal an effective amount of a venlafaxine derivative to treat obesity, panic disorder, post-traumatic stress disorder, attention deficit disorder, Gilles de la Tourette syndrome, bulimia nervosa, anxiety etc. |
| 08/09/2001 | US20010012848 An indane-like compounds which can be useful for treating psychosis and other conditions associated with modulation of a muscarinic receptor |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012833 Method for treating neuromuscular disorders and conditions with botulinum toxin types A and B |
| 08/09/2001 | US20010012828 Intraspinal botulinum toxin for treating pain |
| 08/09/2001 | US20010012627 Neurotransmitter transporter SC6 |
| 08/09/2001 | US20010012626 Polynucleotides encoding Presenilin 1 (PS1); diagnosing a patient having an increased likelihood of contracting Alzheimer's disease |
| 08/09/2001 | DE10004790A1 Plaster-form transdermal therapeutic system containing zaleplon, especially for use as hypnotic agent, providing safe and controlled drug delivery |
| 08/09/2001 | DE10004572A1 Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel New positive allosteric AMPA-receptor modulators (PAARM), to processes for their preparation and their use as medicaments |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399644A1 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399545A1 Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399080A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398250A1 Interaction of nmda receptor with protein tyrosine phosphatase |
| 08/09/2001 | CA2397790A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369050A1 Methods for preventing or attenuating pathoangiogenic conditions |
| 08/08/2001 | EP1122257A1 Benzimidazole compounds as ORL1-receptor agonists |
| 08/08/2001 | EP1122243A1 Novel imidazoles with anti-inflammatory activity |
| 08/08/2001 | EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 08/08/2001 | EP1121439A2 Methods and compositions for inhibiting neoplastic cell growth |
| 08/08/2001 | EP1121436A2 Non-desensitizing ampa-receptors |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121429A2 Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121376A1 Pregnane glucuronides |
| 08/08/2001 | EP1121372A1 Adenine derivatives |
| 08/08/2001 | EP1121362A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity |
| 08/08/2001 | EP1121360A1 Il-8 receptor antagonists |
| 08/08/2001 | EP1121359A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 08/08/2001 | EP1121356A1 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 08/08/2001 | EP1121354A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3? agonists or antagonists |
| 08/08/2001 | EP1121345A1 Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1- 2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
| 08/08/2001 | EP1121342A1 Diaminopropionic acid derivatives |
| 08/08/2001 | EP1121157A1 A novel component in the hedgehog signalling pathway |
| 08/08/2001 | EP1121140A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 08/08/2001 | EP1121139A1 Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid |
| 08/08/2001 | EP1121131A2 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 08/08/2001 | EP1121127A1 Oral pharmaceutical compositions containing buprenorphin |
| 08/08/2001 | EP1121126A1 Method for treating schizophrenia and means used in said method |
| 08/08/2001 | EP1121125A1 Pharmaceutical formulations for use in estrogen deprivation syndrome |
| 08/08/2001 | EP1121124A1 Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine |
| 08/08/2001 | EP1121122A1 Treatment of depression |
| 08/08/2001 | EP1121119A1 A new composition |
| 08/08/2001 | EP1121116A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 08/08/2001 | EP1121115A1 Pufa supplements |
| 08/08/2001 | EP1121114A1 Method for the treatment of mania and bipolar disorder |
| 08/08/2001 | EP1121109A2 Opioid analgesic |
| 08/08/2001 | EP1121107A2 Sertraline oral concentrate |
| 08/08/2001 | EP1121104A2 New sustained release oral formulations |
| 08/08/2001 | EP1121099A1 Pharmaceutical composition with gastric residence and controlled release |
| 08/08/2001 | EP0869956B1 Pharmaceutical compositions |
| 08/08/2001 | EP0841918B1 Thrombin inhibitors |
| 08/08/2001 | EP0815112B1 Process for isolating galanthamine |
| 08/08/2001 | CN1307632A Ependymal neural stem cells and method for their isolation |
| 08/08/2001 | CN1307590A Treating and diagnosing macrophage-mediated diseases using FC receptor ligands |
| 08/08/2001 | CN1307579A Substituted triazolo-pyridazing derivative, pharmaceutical composition made therefrom |
| 08/08/2001 | CN1307576A Serotongergic agents |
| 08/08/2001 | CN1307574A Indolyl derivatives as serotonergic agents |
| 08/08/2001 | CN1307573A Indolyl derivatives and serotonergic agents |
| 08/08/2001 | CN1307569A New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralines and their use |
| 08/08/2001 | CN1307567A 1,5 benzodiazepine derivatives |
| 08/08/2001 | CN1307562A Antipsychotic indolyl derivatives |
| 08/08/2001 | CN1307561A Novel VLA-4 inhibitor: oMePUPA-V |
| 08/08/2001 | CN1307479A Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression |
| 08/08/2001 | CN1306835A External-use medicine for treating facial palsy and its preparation |
| 08/08/2001 | CN1306832A Analgesic composition |
| 08/08/2001 | CN1306819A Preparation of isation medicine for preventing and treating senile neuropathy |